Press Releases

LOS ANGELES, May 20, 2024 /PRNewswire-PRWeb/ -- Circularity Healthcare, maker of D'OXYVA, the only proprietary microcirculatory and transdermal delivery system of its kind with breakthrough clinical evidence, today announced the launch of a nationwide at-home safety and efficacy study open to participants from across the United States. D'OXYVA, a non-invasive, low-risk regenerative technology, has started enrolling participants suffering from underlying chronic conditions such as severe cardiovascular, diabetic, neurological conditions, and chronic pain, following positive results from similar pivotal trials.

"We have always felt that we needed definitive data on chronic conditions," said Gary Goodman BS, BS, RN, lead principal investigator of the study. "As such, we are conducting this at-home safety and efficacy study and are looking to recruit people with various backgrounds who would benefit from D'OXYVA to target the autonomic nervous system rapidly and address chronic conditions to boost blood flow and tissue oxygenation. Allowing patients from across the U.S. to take part expands our data collection."

D'OXYVA's cutting-edge transdermal delivery system significantly improves microcirculation, tissue perfusion, and autonomic nervous system functions. The extensive, decade-long clinical research has produced high success rates, resulting in powerful results. Additionally, zero adverse events have been reported with over 90 percent of daily users getting relief within 2-4 weeks. D'OXYVA addressed the demand for innovative technologies that cater to pressing unmet medical needs across a spectrum of chronic conditions.

The ongoing study can be completed from anywhere without visiting the private clinic. It will demonstrate how private clinics can administer D'OXYVA (deoxyhemoglobin vasodilator) technology for various patients at home. Participants will pay a discounted price for D'OXYVA and will be provided with diagnostic tools for free with the purchase of each product bundle by the clinic as needed. Additionally, results will be analyzed and reported monthly to the private clinic.

"As a registered nurse, my primary responsibility is to advocate for all individuals and this study allows me and other RNs to do so nationwide," said Goodman. "We serve as intermediaries among patients, physicians, and healthcare providers, so the RN role in this at-home study is critical. We are championing their health by encouraging our eligible patients to participate in the study making a substantial impact on their well-being."

To learn how to get involved in the study, reach out to info@doxyva.com.

About Circularity Healthcare

Circularity Healthcare, LLC, headquartered in Los Angeles, U.S.A. is an emerging world leader in proprietary circulatory health and non-invasive delivery technologies, committed to helping improve lives by developing, manufacturing, and marketing consumer health and wellness products. Circularity specializes in groundbreaking non-invasive technologies for highly portable medical gas-powered transdermal delivery systems and is pursuing regulatory approvals worldwide for treatment of a host of disease states.